<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240101060587N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-28</date_registration>
      <primary_sponsor>CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan</primary_sponsor>
      <public_title>To determine which surgical tool is better for skin incisions in maxillofacial surgeries, whether it's scalpel or diathermy</public_title>
      <acronym>Not applicable</acronym>
      <scientific_title>Randomised Clinical Trial on scalpel versus diathermy skin incision in maxillofacial surgery.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>82</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74755</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Other design features: Sample size of 82 (with 41 participants in each group), Randomization description: Method: Simple Randomization
Unit: Individual 
Stratified randomization
Computer randomization using software 
2 parallel groups (both would be intervention groups)
Allocation will be concealed from the patient and principal investigator (assessor) but not from the primary surgeon (Double Blind), Blinding description: Patients will provide consent to be part of the trial. After which they would be randomized using computer software into two parallel intervention groups. Patients won't be aware of the group they belong to. They would be handed sealed envelope of their id number, only the surgeon and his/her operatiom theatre team would know the group to which the patient would belong to and they would record their findings against patients ID number without mentioning the group of the patient (whether scalpel group or diathermy group). The post surgery assessor and ward staff would also be blind to the randomization.

So, in short,  Patients will be randomly assigned into two mutually exclusive groups each experiencing a different incision tool. The two groups will be scalpel group and diathermy group. Randomly, a sealed card with either scalpel or diathermy incision option inside, will be drawn, to decide which tool will be applied.
The surgeon performing the incision shall not be blinded, however the patient and the assessor will be blind to the incision tool used.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Incision time, intraoperative bleeding from Incision and post surgical pain after Incision using scalpel or diathermy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Scalpel Incision Group. No. 15 disposable scalpel with no.3 reusable sterilizable handles. Skin incisions, mucosal incisions would be larger than 2 cm in maxillofacial region. incisional time and intraoperative blood loss during incision shall be calculated during the surgery, for post-operative skin incision site pain, regular follow up with patients will be carried out over a period of three months to determine extent of postoperative pain. Prospective data will be collected in quantitative form. post-op visits (upto 3 months). Regular follow up with the patients will be carried out daily for five days, at one week- for assessment of acute pain if any, 4 weeks, and 3 months- for assessment of chronic pain if any. Intervention 2: Intervention group: Diathermy group. Incisions on skin and mucosal layers of maxillofacial region made using diathermy using Monopolar and Bipolar cautery at 0.5 to 3 MHz. incisional time and intraoperative blood loss during incision shall be calculated during the surgery, for post-operative skin incision site pain, regular follow up with patients will be carried out over a period of three months to determine extent of postoperative pain. Prospective data will be collected in quantitative form. post-op visits (upto 3 months). Regular follow up with the patients will be carried out daily for five days, at one week- for assessment of acute pain if any, 4 weeks, and 3 months- for assessment of chronic pain if any.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is CMH Lahore doesn't allow sharing data of patients</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Vaffa Shahid Khan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Oral and Maxillofacial Surgery Department, CMH Lahore Medical College and Institute of Dentistry, Abdur Rehman Road, Lahore Cantt, Punjab, Pakistan</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54810</zip>
        <telephone>+92 321 4481828</telephone>
        <email>vaffasaad@gmail.com</email>
        <affiliation>CMH LAHORE MEDICAL COLLEGE AND INSTITUTE OF DENTISTRY</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Vaffa Shahid Khan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Oral and Maxillofacial Surgery Department, CMH Lahore Medical College and Institute of Dentistry, Abdur Rehman Road, Lahore Cantt, Punjab, Pakistan</address>
        <city>Lahore</city>
        <country1>Pakistan</country1>
        <zip>54810</zip>
        <telephone>+92 321 4481828</telephone>
        <email>vaffasaad@gmail.com</email>
        <affiliation>CMH LAHORE MEDICAL COLLEGE AND INSTITUTE OF DENTISTRY</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 30 years old to 60 years old
Maxillofacial region surgery including tumor resection, neck dissection, parotid surgery, Maxillofacial trauma surgery
Incision length 2 cm to 10 cm
Patients who give consent</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who have active wound infections, anemia
Patients who are on corticosteroids, anticoagulant, anti platelet medication
Any previous scar or keloid
Patients with known connective tissue and skin disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Scalpel Incision Group. No. 15 disposable scalpel with no.3 reusable sterilizable handles. Skin incisions, mucosal incisions would be larger than 2 cm in maxillofacial region. incisional time and intraoperative blood loss during incision shall be calculated during the surgery, for post-operative skin incision site pain, regular follow up with patients will be carried out over a period of three months to determine extent of postoperative pain. Prospective data will be collected in quantitative form. post-op visits (upto 3 months). Regular follow up with the patients will be carried out daily for five days, at one week- for assessment of acute pain if any, 4 weeks, and 3 months- for assessment of chronic pain if any.</i_keyword>
      <i_keyword>Intervention group: Diathermy group. Incisions on skin and mucosal layers of maxillofacial region made using diathermy using Monopolar and Bipolar cautery at 0.5 to 3 MHz. incisional time and intraoperative blood loss during incision shall be calculated during the surgery, for post-operative skin incision site pain, regular follow up with patients will be carried out over a period of three months to determine extent of postoperative pain. Prospective data will be collected in quantitative form. post-op visits (upto 3 months). Regular follow up with the patients will be carried out daily for five days, at one week- for assessment of acute pain if any, 4 weeks, and 3 months- for assessment of chronic pain if any.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Incision Time. Timepoint: Incision Time (time taken from the initial skin incision till end of incision), will be noted and calculated in seconds per unit wound area (sec/cm2). Method of measurement: Stop watch.</prim_outcome>
      <prim_outcome>Intraoperative blood loss. Timepoint: Intraoperative blood loss will be measured from the point when incision begins to the point patient is shifted out of the operation theater to the ward and eventually discharged from the ward. Every 6 hours after the surgery till the patient is discharged from the hospital (day 2 to day 6). Method of measurement: Intraoperative blood loss will be measured by weighing the total weight of blood-soaked gauze from the patients.</prim_outcome>
      <prim_outcome>Pain. Timepoint: Regular follow up with the patients will be carried out, every 6 hours post surgery on day 1 and day 2, daily for the next five days, at one week- for assessment of acute pain if any, 4 weeks, and 3 months- for assessment of chronic pain if any. Method of measurement: Visual analogue scale for pain.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-01-12</approval_date>
        <contact_name>Ethical Review Committee, CMH Lahore Medical College and Institute of Dentistry</contact_name>
        <contact_address>CMH Lahore Medical College and Institute of Dentistry, Abdur Rehman Road, Lahore Cantt, Pakistan Lahore Punjab Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
